Previously, we have reported amyotrophic lateral sclerosis (ALS) families with multiple mutations in major ALS-associated genes. These findings provided evidence for an oligogenic basis of ALS. In our present study, we screened a cohort of 755 sporadic ALS patients, 111 familial ALS patients (97 families), and 765 control subjects of Dutch descent for mutations in vesicle-associated membrane protein B (VAPB). We have identified 1 novel VAPB mutation (p.V234I) in a familial ALS patient known to have a chromosome 9 open reading frame 72 (C9orf72) repeat expansion. This p.V234I mutation was absent in control subjects, located in a region with high evolutionary conservation, and predicted to have damaging effects. Taken together, these findings provide additional evidence for an oligogenic basis of ALS.
Introduction
Amyotrophic lateral sclerosis (ALS) is a complex neurodegenerative disorder of upper and lower motor neurons. Recently, we screened 97 families with familial ALS (FALS) for mutations in TAR DNA-binding protein (TARDBP), fused in sarcoma/translated in liposarcoma (FUS/TLS), superoxide dismutase-1 (SOD1), angiogenin (ANG), and chromosome 9 open reading frame 72 (C9orf72) . In 5 of these families we identified multiple mutations, which is higher than one might expect on the basis of chance (p ϭ 1.57 ϫ 10 Ϫ7 ). We demonstrated that C9orf72 repeat expansions were combined with TARDBP, FUS/TLS, and SOD1 mutations, and that ANG mutations were also combined with TARDBP and FUS/TLS mutations. These findings supported an oligogenic etiology of ALS. In our cohort of FALS patients, we had not yet determined the mutation frequency of vesicle-associated membrane protein B (VAPB). A mutation in VAPB (p.P56S) was initially reported in Brazilian families with motor neuron disease (Nishimura et al., 2004) . Families with VAPB mutations demonstrate a wide range of phenotypes: their age at onset varied from 25 to 55 years of age, their disease progression from 2 to 30 years, and they were diagnosed with late-onset spinal muscular atrophy, atypical ALS, or typical ALS (Nishimura et al., 2004) . Moreover, several patients were also described with autonomic abnormalities, including chronic intestinal constipation, and sexual dysfunction (Marques et al., 2006) . Subsequently, this mutation has been described in patients of Brazilian, Japanese, and European origin (Funke et al., 2010; Landers et al., 2008; Millecamps et al., 2010) . Recently, a second missense mutation in VAPB (p.T46I) was identified in a cohort of FALS patients from the United Kingdom (Chen et al., 2010) . We investigated the mutation frequency of VAPB mutations in a well-genotyped cohort of ALS patients and control subjects of Dutch descent.
Methods
The study population consisted of 755 patients with sporadic ALS (SALS) and 111 patients with FALS (from 97 different families). All patients were seen at national referral centers for neuromuscular diseases (University Medical Center Utrecht, Academic Medical Center, Amsterdam, and Radboud University Nijmegen Medical Center) and diagnosed with ALS according to the El Escorial criteria (Brooks et al., 2000) . Their baseline characteristics are shown in Supplementary Table 1. We also included 765 control subjects of Dutch descent. Patient material was obtained with approval of the Institutional Review Board, and participants gave informed consent. All FALS patients, and large cohorts of SALS patients and control subjects, had been screened for mutations in TARDBP, FUS/TLS, SOD1, ANG, and C9orf72 (van Blitterswijk et al., 2012) .
We screened coding regions of VAPB (NM_004738) for mutations. Previously described primers were used for amplification by touchdown polymerase chain reaction (Chen et al., 2010) . For sequencing and data analysis BigDye Terminator 3.1 sequencing kit (Applied Biosystems, Foster City, CA, USA), DNA Analyzer 3730XL (Applied Biosystems), and PolyPhred were used (Nickerson et al., 1997) . We confirmed mutations on genomic DNA, and used PolyPhen-2 to predict the impact of these mutations on the structure and function of VAPB (genetics.bwh.harvard.edu/ pph2/; version 2.1.0, released May 2011). PolyPhen-2 values were also used for the variable-threshold test to analyze grouped mutations (Price et al., 2010) . This statistical test increases statistical power, and uses a threshold that separates mutations that are likely to be detrimental or nondetrimental. The program R was used to perform this statistical analysis (CRAN; www.r-project.org).
Results
In our Dutch cohort we identified VAPB variants in 3.1% of the FALS families, 1.5% of the SALS patients, and 1.4% of the control subjects (Table 1) . Only 1 of these variants, p.V234I, had not been detected in control subjects (1.0% of FALS). The variable-threshold test displayed that there was no significant difference in mutational burden between patients and control subjects, no matter whether we took potential damaging effects of mutations into account (p ϭ 0.49) or not (p ϭ 0.53).
We used PolyPhen-2 to predict the effects of these VAPB variants, and demonstrated that p.S158N and p.V234I could have damaging effects (Table 1) . Because p.S158N was also detected in 1 control subject, this variant most likely represents a benign rare polymorphism; p.V234I, on the other hand, was not detected in control subjects. The pathogenicity estimate of the p.V234I mutation was 0.79 (values above 0.50 indicate pathogenicity) with a sensitivity of 0.85 and specificity of 0.93. Moreover, it is located in a region that is highly conserved across species, and appears to cause small changes to ␣-helixes located within the VAPB protein (Supplementary Fig. 1 ). This VAPB mutation was detected in a patient that also harbored a C9orf72 repeat expansion (Supplementary Fig. 1 ). She developed weakness in her right leg at 65 years of age, without signs of frontotemporal dementia (FTD), and died after 34 months (Supplementary Table 2 ). Her mother, uncle, and grandmother had also died of ALS ( Supplementary Fig. 2 ). None of her family members had been diagnosed with FTD. 
Discussion
Our study identified 1 novel VAPB mutation (p.V234I) that was absent in control subjects, located in a region with high evolutionary conservation, and predicted to be pathogenic. Currently, only 2 pathogenic VAPB mutations have been reported. The first mutation, p.P56S, was identified in motor neuron disease families with phenotypic heterogeneity (Nishimura et al., 2004) . The second mutation, p.T46I, was recently detected in 1 FALS patient from the United Kingdom (Chen et al., 2010) . VAPB has 3 conserved domains: an N-terminal immunoglobulin-like ␤-sheet that resembles the nematode major sperm protein (amino acid 1-125) and contains a double phenylalanine in an acidic tract, a central coiled-coil domain (amino acid 158 -211), and a C-terminal transmembrane domain (amino acids 220 -243) (Lev et al., 2008) . The p.P56S, and p.T46I mutations are both located within the nematode major sperm protein; the p.V234I mutation is located in the transmembrane domain. VAPB is known to be involved in many cellular processes, including lipid metabolism, membrane trafficking, the unfolded protein response, microtubule organization, and homeostatic-and stress-signaling systems in the endoplasmic reticulum (ER) (Gkogkas et al., 2008; Kanekura et al., 2009; Lev et al., 2008) . Mutations in VAPB have already been shown to cause cytoplasmic transactive response DNA-binding protein 43 (TDP-43) accumulations, lead to ER disorganization, and increase the vulnerability of motor neuron cells to ER stress-induced death (Chen et al., 2010; Tudor et al., 2010) .
The identified p.V234I mutation was present in 1 FALS patient, which also harbored a C9orf72 repeat expansion. This repeat expansion has recently been identified as the most common genetic cause of ALS (Dejesus-Hernandez et al., 2011; Renton et al., 2011) . We have already reported that C9orf72 repeat expansions can be detected in approximately 37% of the FALS families in The Netherlands (van Rheenen et al., 2012) . In addition, we have shown that these repeat expansions can be identified in FALS patients with TARDBP (p.N352S), FUS/TLS (p.Q210H), or SOD1 (p.D90A) mutations . A recent study in Sardinia also reported C9orf72 repeat expansions in patients with TARDBP (p.A382T) mutations (Chiò et al., 2012) . One of their patients had ALS and FTD, his age at onset was 43 years, his disease duration was 34 months, and both his parents had also been diagnosed with ALS and FTD. Furthermore, they described another patient that developed ALS without FTD at 35 years of age; this patient was tracheotomized after 25 months, and none of his family members was known to have ALS or FTD (reduced penetrance). They argued that the age at symptom onset was influenced by the genetic burden of the individual, and that these patients demonstrated a relatively severe disease course. We, however, could not detect significant differences in age at onset between patients with mutations in 1 ALS-associated gene and patients with mutations in multiple ALS-associated genes . The detection of mutations in multiple ALS-associated genes, and their detection in families with reduced penetrance and/or apparently sporadic patients (Chiò et al., 2012; van Blitterswijk et al., 2012) , does suggest that the etiology of ALS is more complex than previously thought.
In our present study, we report a novel VAPB mutation in a patient with a C9orf72 repeat expansion. This repeat expansion has been reported in patients with a range of clinical phenotypes, including FTD, ALS, ALS-FTD, and progressive muscular atrophy (Dejesus-Hernandez et al., 2011; Renton et al., 2011; van Rheenen et al., 2012) . VAPB mutations have been detected in patients with phenotypic heterogeneity as well (Nishimura et al., 2004) . We, therefore, hypothesize that these phenotypic differences can be attributed to interactions between ALS-associated genes, thus emphasizing the complex oligogenic etiology of neurodegenerative diseases, and of ALS in particular.
